Clene submits CNM-Au8 new drug application to FDA for ALS

Clene submitted a New Drug Application to the FDA seeking accelerated approval of CNM-Au8 for treating ALS and is preparing the confirmatory Phase 3 RESTORE-ALS study.Material DetailsContext by AI AnalystThis is a late-stage regulatory step following prior clinical work on CNM-Au8 in ALS. A formal…